Neuromyers Optica Spectrum Disorder

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2026-04-13
Clinical Trial Update: A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders [Phase 3]
Phase III study of RC18 for neuromyelitis optica spectrum disorders has been terminated; no results are provided in this update.